We are live on ! Find out more
Pacer Advisors

Pacer Advisors Portfolio holdings

AUM $35.6B
1-Year Est. Return 18.19%
This Fund
S&P 500
This Quarter Est. Return
+10.34%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$5.32B
AUM Growth
+$623M
Cap. Flow
+$473M
Cap. Flow %
8.88%
Top 10 Hldgs %
31.02%
Holding
1,563
New
308
Increased
332
Reduced
859
Closed
60

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$80.9M
2
MSFT icon
Microsoft
MSFT
+$63.9M
3
AMZN icon
Amazon
AMZN
+$61.8M
4
META icon
Meta Platforms (Facebook)
META
+$26.4M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$24.2M

Sector Composition

Rank Sector Weight
1 Real Estate 18.33%
2 Technology 16.44%
3 Consumer Discretionary 8.8%
4 Healthcare 7.69%
5 Communication Services 7.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CVM icon
1326
CEL-SCI Corp
CVM
$21M
$30K ﹤0.01%
85
-40
-32% -$15.8K
KROS icon
1327
Keros Therapeutics
KROS
$199M
$30K ﹤0.01%
+432
New +$27.2K
CPRX
1328
DELISTED
Catalyst Pharmaceutical
CPRX
$29K ﹤0.01%
8,608
-737
-8% -$2.48K
DTIL icon
1329
Precision BioSciences
DTIL
$185M
$29K ﹤0.01%
+118
New +$28.9K
KRNT icon
1330
Kornit Digital
KRNT
$708M
$29K ﹤0.01%
+325
New +$25K
ISEE
1331
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$29K ﹤0.01%
+4,264
New +$27.3K
TCRT icon
1332
Alaunos Therapeutics
TCRT
$4.64M
$28K ﹤0.01%
75
+28
+60% +$11.1K
ANIK icon
1333
Anika Therapeutics
ANIK
$202M
$27K ﹤0.01%
605
-202
-25% -$7.67K
FVRR icon
1334
Fiverr
FVRR
$417M
$27K ﹤0.01%
+140
New +$25.3K
STOK icon
1335
Stoke Therapeutics
STOK
$1.83B
$26K ﹤0.01%
+427
New +$19.6K
NBLX
1336
DELISTED
Noble Midstream Partners LP
NBLX
$26K ﹤0.01%
2,456
-483
-16% -$4.48K
KRRO icon
1337
Korro Bio
KRRO
$151M
$25K ﹤0.01%
+14
New +$18.5K
QGEN icon
1338
Qiagen
QGEN
$8.72B
$25K ﹤0.01%
+446
New +$23.8K
GERN icon
1339
Geron
GERN
$930M
$24K ﹤0.01%
+14,878
New +$27.1K
SID icon
1340
Companhia Siderúrgica Nacional
SID
$1.46B
$24K ﹤0.01%
+3,962
New +$16.9K
CUE icon
1341
Cue Biopharma
CUE
$127M
$23K ﹤0.01%
61
+28
+85% +$11.2K
SRRK icon
1342
Scholar Rock
SRRK
$5.92B
$23K ﹤0.01%
+476
New +$17.3K
PBFX
1343
DELISTED
PBF LOGISTICS LP
PBFX
$22K ﹤0.01%
2,386
+76
+3% +$672
ATHX
1344
DELISTED
Athersys, Inc. Common Stock
ATHX
$22K ﹤0.01%
506
-155
-23% -$7.05K
RNAM
1345
DELISTED
Avidity Biosciences
RNAM
$21K ﹤0.01%
+839
New +$24.5K
TIMB icon
1346
TIM SA
TIMB
$9.45B
$21K ﹤0.01%
1,541
+621
+68% +$7.75K
AMTI
1347
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$21K ﹤0.01%
+691
New +$21.9K
GBIO
1348
DELISTED
Generation Bio
GBIO
$20K ﹤0.01%
+70
New +$22.5K
SBSW icon
1349
Sibanye-Stillwater
SBSW
$5.93B
$20K ﹤0.01%
+1,273
New +$17.1K
NGNE icon
1350
Neurogene
NGNE
$663M
$19K ﹤0.01%
+67
New +$16.4K

Similar funds

Pacer Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Pacer Advisors held 1,563 positions worth $5.32B, up 13% from $4.7B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Pacer Advisors deployed $473M of net new capital in Q4 2020, opening 308 new positions and adding to 332 existing holdings. Its largest new stake was Chindata Group Holdings Limited American Depositary Shares: 1,166,530 shares worth $27.9M.

By sector, the portfolio is most concentrated in Real Estate at 18% of assets, up from 17% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Apple, an estimated $80.9M trimmed.

  • Pacer Advisors's largest Q4 2020 buy was Chindata Group Holdings Limited American Depositary Shares: 1,166,530 shares worth $27.9M.
  • Pacer Advisors added most to Equinix in Q4 2020, an estimated $43.7M increase.
  • Pacer Advisors's biggest Q4 2020 reduction was Apple, cutting an estimated $80.9M.
  • Pacer Advisors fully exited INDUS Realty Trust, Inc. (MD) Common Stock in Q4 2020, selling an estimated $1.83M.
  • Pacer Advisors's ten largest holdings make up 31% of its $5.32B portfolio in Q4 2020.
  • Pacer Advisors opened 308 new positions and closed 60 in Q4 2020.
  • Pacer Advisors's portfolio value rose 13% quarter-over-quarter to $5.32B.

Based on Pacer Advisors's 13F filing for Q4 2020, filed 20 Jan 2021.